Minnesota Proposes to Reduce Opioid Product Registration Fees Related to Hospitals
FDA Law
JUNE 28, 2021
Richardson — A recent proposed amendment to Minnesota’s Opiate Product Registration Fee appears intended to ensure continued availability of certain opiate products at hospitals. Whether HF33 is enacted or not, state legislative initiatives aimed at combatting the opioid epidemic continue to be a moving target for opioid manufacturers.
Let's personalize your content